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Impact of Antibiotic usage on resistance in Microorganisms; Urinary Tract
Infections with E-coli as a case in point
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Deptartments of Pathology and Microbiology*, The Aga Khan University, Karachi.

Abstract
Objectives: In this study, we sought to establish a correlation between consumption of flouoroquinolones in our
hospital and the emergence of ofloxacin resistant strains of E.coli in the urinary specimens. Data of all urinary
samples, received at Aga Khan University Hospital between January 1995 and December 2002, was retrieved
and analyzed. Specimens yielding E-coli as an isolate were included in this study.
Methods: E. coli Isolates showing >103 colonies were identified using standard microbiological techniques.
Antibiotic susceptibility of E-coli was tested using Kirby Bauer disc diffusion method. Antimicrobial usage data,
obtained through hospital Pharmacy as unit utilized per year for Quinolones in different medical and surgical units
was available only for the period of 1997- 2002.
Results: Among 32,722 urinary specimens E.coli (53%) was the most frequent isolate. Steady increase in the
number of ofloxacin resistant E.coli was noted, 24% in 1995 to 55% in 2002. Maximum quinolone resistant E
coli have been observed in Medical units, 41% in 1997 increasing to 70% in 2002, followed by Surgery units
(35% to 54%) and Pediatrics (12 to 38%). Sharp increase in ofloxacin consumption in our hospital, 1997 (28613
units) to 2002 (96880 units) has been observed. Trends in quinolone resistance correlate significantly with utilization in the same period as shown by linear regression.
Conclusion: E- coli resistance against most antibiotics has been on a rise particularly for quinolones. The utilization of quinolones correlates with increasing resistance in our hospitalized patients (JPMA 54:472;2004).

Introduction
The introduction of quinolones was a breakthrough
in the treatment of infectious diseases. Nalidixic acid was
the first quinolone introduced in 1960 and newer quinolone
agents (oxalinic acid, pipemidic acid and cinoxacin) were
added in 1970. More potent fluroquinolones (ciprofloxacin
and norfloxacin) were developed in 1980s, having a broad

antimicrobial activity and oral availability making them the
leading antimicrobial agents against a wide variety of infectious diseases.1,2
Resistance to fluoroquinolone was first reported in
1990s and it has increased eversince.3,4 Frequent use of
ciprofloxacin has been associated with resistance not only
to quinolones but also to other antimicrobial agents like

cloxacillin in Staph aureus as it leads to expression of highlevel oxacillin-resistance in these organisms. A recently
published paper has discussed that exposure to levofloxacin
and ciprofloxacin is a significant risk factor for isolation of
MRSA.5,6 Association between use of quinolones and resistance has been reported throughout the world.8,9
Current International recommendations state that
Institutional antimicrobial prescription policies must be
developed in order to control the utilization of antibiotics to
prevent antimicrobial resistance. The development of such
policies however necessitate that resistance and antimicrobial usage data be analyzed according to location and areas
with excessive utilization and rising resistance be identified
and targeted in order to decrease consumption and hence
resistance.
Increasing resistance to ciprofloxacin amongst
microorganisms has been noticed in our hospital. In this
study we sought to find out the utilization of quinolones in
different clinical services and to correlate it with the resistance trend seen in microorganisms. Urinary isolates of Ecoli from these areas have been used as representative
organisms to correlate resistance to quinolones seen against
antimicrobial load.

Material and Methods
The study was conducted in a 350 bedded teaching
hospital backed by a highly sophisticated clinical laboratory. Microbiological results of all clinical specimens were
stored in the database of Information System Department
(ISD) of the hospital.
Setting and Study period
Data of all urinary samples, received between
January 1995 and December 2002, was retrieved and analyzed. Specimens yielding E-coli were included in this
study,
Antibiotic utilization data
Antimicrobial usage data was obtained through our
hospital pharmacy service. Consumption was expressed as
unit utilized per year for quinolones in different medical,
surgical and pediatric units of the hospital for the period of
1997- 2002.
Microbiological methods
All urinary samples were inoculated on Cystein
Lactose Electrolyte Deficient (CLED) medium (oxoid)
using a 0.01ul calibrated loop such that growth of >103
colonies of a pathogen considered significant, plates were
incubated at 37°C for 24-48 hours. Isolates showing >103
colonies were identified using standard microbiological
techniques. E-coli were identified on the basis of triple

sugar iron agar (TSI), sulphide indole motility (SIM) test
medium, citrate utilization and urea production.10,11
Antimicrobial susceptibility testing
Antibiotic susceptibility of E-coli was tested using
Kirby Bauer disc diffusion method.22 The panel of antibiotics routinely tested for urinary strains of E.coli included
Ampicillin (10ug), Trimethoprim-sulphamethoxazole (25ug),
Amikacin (30ug), Nitrofurantoin (300ug), Gentamicin (10ug),
Ceftriaxone (30ug), Ofloxacin (5ug), Nalidixic acid (30ug)
and Pipemedic acid (20ug) (Oxoid).12
Statistical analysis
Data was analyzed using SPSS; Significance of correlation between percent resistance and drug utilization was
assessed using linear regression analysis.

Results
During the study period, 32,722 urinary specimens
were processed. E.coli was the most frequent isolate (53%)
in the total positive specimens followed by Pseudomonas
(17%) and Enterobacter (9.3%). Over the study duration a
steady increase in the number of ofloxacin resistant E.coli
was noted, 24% in 1995 to 55% in 2002. On categorization
of the data according to the clinical services, maximum
number of these resistant strains were isolated from patients
in Medical units; 41% in 1997 increasing to 70% in 2002,
followed by Surgery (35%to 54%) Surprisingly, the
ofloxacin resistant strains of E.coli were also isolated from
urinary samples of Pediatric unit where use of quinolone is
limited (Figure 1).
The ofloxacin utilization data of hospital pharmacy
for the period of 1997-2002 revealed a sharp increase in the
consumption of ofloxacin in our hospital (Figure 2).There
was a statistically significant correlation between the
increase in the incidence of ofloxacin resistant strains of
E.coli and the ofloxacin utilization in the hospital (Figure 3).
The trend in antimicrobial resistance shows a strong
positive relation to quinolone utilization in Medical (R
=0.970) and Pediatrics units (R=0.980) while the association for the surgical unit was relatively weak positive estimated to be (R = 0.705).
Furthermore in addition to increasing resistance to
quinolones a significant gradually increasing trend was
observed for almost all other antibiotics tested including
Ampicillin, Ceftriaxone, Cotrimoxazole, Gentamicin and
Amikacin has also been noted (Table).

Discussion
Our study demonstrates increasing prevalence of
ofloxacin resistance in the urinary E-coli isolates.
Furthermore, we also show a clear association of this

The trend in antimicrobial resistance shows a strong
positive relation to quinolone utilization in Medical (R
=0.970) and Pediatrics units (R=0.980) while the association for the surgical unit was relatively weak positive estimated to be (R = 0.705).
Furthermore in addition to increasing resistance to
quinolones a significant gradually increasing trend was
observed for almost all other antibiotics tested including
Ampicillin, Ceftriaxone, Cotrimoxazole, Gentamicin and
Amikacin has also been noted (Table).

Discussion
Our study demonstrates increasing prevalence of
ofloxacin resistance in the urinary E-coli isolates.
Furthermore, we also show a clear association of this
increasing incidence of resistance with the increasing utilization of ofloxacin amongst in-patients.
Prior use of the fluoroquinolones has been identified
as a risk factor for the emergence of the resistant strains.10,11
Our results support this association indirectly. Majority of
the resistant strains emerged from the medical wards that
cater for patients with a variety of underlying diseases such
as febrile neutropenia, typhoid fever and chronic urinary
tract infections. Ciprofloxacin is often used in these patients
either empirically or as first line drug. Similarly, the statistically significant increase in per unit utilization of the fluoroquinolones in the medical unit also supports this association.
Use of quinolones in pediatric patients had been
restricted due to the published reports of quinolone association with arthropathy, gait abnormalities and articular cartilage lesions in weight bearing joints of juvenile animals.13
Gradual increase in quinolones usage in pediatric patients
has been observed in the recent years mainly due to presence of multidrug resistant organisms where quinolones
may be the only treatment option. Increased usage in pediatric population may also be attributed to the recently published data about relative safety of quinolone use in children.14,15 This increased use has lead to a sharp increase in
quinolone resistance observed in this group of patients as
well.
Fluoroquinolones are the most potent broad-spectrum antibiotics effective in treatment of wide range of
infections.16,17 They exert their antibacterial effects by inhibition of bacterial topoisomerase enzymes, namely, DNA
gyrase (bacterial topoisomerase II) and topoisomerase
IV.4,17 In gram-negative organisms, DNA gyrase is considered the primary target for all quinolones.18,19 Alteration of
target enzyme appears to be the most dominant factor in
expression of resistance to quinolones, other mechanisms
include, decreased up-take and most recently known, plasmid mediated efflux mechanisms.17,18,20

A previously published study from this region has
reported the presence of ESBL producing E-coli strains
resistant to all ß-Lactam antibiotics except cephamycins and
carbapenems.21 Recently published studies have reported
expression of multiple efflux transporter mechanisms like
MexA-MexB-OprM and MexC-MexD-OprJ, RND-type
multidrug efflux pumps AcrB and AcrD in E.coli conferring
resistance to multiple classes of antibiotics including beta
lactams, imipenam and tetracycline as also evident in our
study.22,23 Such phenomenon may well explain the fact that
the majority of ofloxacin resistant strains of E-coli also
showed resistance to other unrelated antibiotics.
In conclusion, increasing E- coli resistance against
most antibiotics needs continued local and national surveillance. Particularly the demonstration of a direct association
of utilization with increasing resistance against quinolones
points towards the need for improvement in antibiotic prescription polices to curtail such a trend.
Our study has moreover identified specific areas
where antimicrobial prescription policies require review. In
health care centers with limited resources it may be difficult
to implement control policies across board; it is thus important to identify specific areas requiring greater attention.
Presence of multidrug resistant organisms indicates a need
for restricted and judicious use of antimicrobial agents.
Empirical treatment of infections should be based on local
surveillance data.
Limitation and Suggestion
As this study was conducted in a single hospital,
results can not be generalized at national level, but authors
believe that a similar scenario must be prevailing in other
secondary and tertiary care hospitals therefore we suggest
that further multicenter studies should be carried out to
assess the severity of the problem which will facilitate in
development of guidelines for appropriate antibiotics usage.
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